Moderna Inc (NASDAQ:MRNA) has reportedly achieved a significant victory at the European Patent Office (EPO) in its ongoing ...
Moderna Inc. gained US approval for its RSV vaccine in older adults, giving the biotech company a second product as it seeks ...
The US Food and Drug Administration announced Friday that it had advised the makers of the Covid-19 vaccines to formulate ...
Manufacturing is underway and doses of Moderna’s Spikevax 2024-2025 formula will be ready to ship as early as August, pending ...
Synopsys VC Verification IP (VIP) for Fibre Channel is designed to thoroughly verify Fibre Channel designs using both random and directed simulation. The Fibre Channel VIP provides full protocol ...
The decision is a win for Moderna, which needs another revenue source amid plunging demand for its Covid vaccine, its only commercially available product.
Synthesia's new technology is impressive but raises big questions about a world where we increasingly can’t tell what’s real. The FDA is poised to approve the notorious party drug as a therapy. Here’s ...
The U.S. health regulator on Friday advised COVID-19 vaccine manufacturers that new shots for the fall 2024 campaign should ...
Another new version of the Covid-19 vaccine will probably be coming this fall. The US Food and Drug Administration’s ...
Moderna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory approval, the company said Friday, marking the first time a messenger RNA vaccine has been approved ...
The U.S. Food and Drug Administration has approved Moderna's respiratory syncytial virus vaccine, the company announced on Friday, giving it a shot at much-needed new revenue from a second product.
The facility, which will be the drugmaker's first end-to-end ADC production site, will be supported by the Singapore Economic Development Board. The company did not provide details on the possible ...